HELSINKI, June 2, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced its raised mid-term business targets for 2025.

HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV ...

Boehringer Ingelheim has struck a deal to apply Nanoform's nanoparticle technology to its preclinical pipeline prospects. The master services agreement positions the partners to work to improve ...

The agreement specifies that Nanoform will provide non-GMP nanomaterial to Takeda for in-vivo studies, the first results of which should be delivered by early 2025. Nanoform, based in Helsinki, ...

Nanoform Finland Plc (Nanoform), the medicine performance enhancing company, announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its ...